26. Addiction and definitions with Robert West, December 19, 2023 (18.54 mins)
In this episode Zoe Swithenbank talks to Professor Robert West about his work on ontologies within addictions. Robert begins by summarising the definitions and constructions that relate to addiction, as well as their meanings and the implications for treatment. He also explains how different definitions can frustrate progress in addiction-related research.

25. Nitrous oxide, addiction and substance use disorder with Sammie Back and Emese Kroon, December 12, 2023 (24.10)
In this episode Dr Elle Wadsworth talks to Sammie Back and Emese Kroon about nitrous oxide. The discussion happened on 8 November 2023, on the day that possession of nitrous oxide became a Class C substance in the UK. The group discuss the existing evidence for harms, addiction and other disorders, exploring this relatively under-researched area.

24. Pregnancy and opioids with Jerry Cochran, December 5, 2023 (20.24)
In this episode Ben Scher talks to Professor Gerald (Jerry) Cochran about his article based on a randomized multisite pilot trial investigating the impact of Patient Navigation. Jerry begins by describing Patient Navigation, explaining how it works and how it can help people stay engaged in care. The research team explored whether this approach helps pregnant people to stay in contact with treatment services.

23. Minimum unit pricing and road traffic accidents with Francesco Manca, November 28, 2023 (25.45 mins)
In this episode Rob Calder talks to Francesco Manca about his research on Scotland's Minimum Unit Pricing (MUP) policy for alcohol, and specifically about the impact that MUP has had on road traffic accidents. Francesco discusses how the research team selected appropriate comparitors to assess whether changes to road traffic accidents could be attributed to MUP. He also talks about how this study compares with previous studies that used similar datasets yet drew different conclusions. He describes how understanding the subtle differences between time frames and outcomes can aid researchers to gain an in-depth understanding of alcohol regulation.

22. Mental health and social care with Amy O'Donnell and Kat Jackson, November 21, 2023 (35.54 mins)
In this episode, Zoe Swithenbank talks to Drs Amy O'Donnell and Kat Jackson about their recent study on how to improve care for people with coexisting heavy drinking and depression. The discuss the theoretical concept of Relational Autonomy and how it influenced their research.

21. Smoking cessation trials with Zoe Swithenbank, October 26, 2023 (25.51 mins) 
In this episode, Rob Calder talks to Zoe Swithenbank about her recent article looking at how to improve research reports on smoking cessation trials. Zoe talks about the challenges of organising an international meeting of experts before the COVID-19 pandemic (before people were used to online working). She talks about some common errors and omissions that researchers make when reporting smoking cessation trials and how these can place limits on scientific progress. She talks about developing the CONSORT-SPI tool to help improve the ability of researchers to draw conclusions across studies.

20. Drug Consumption rooms with Laurence Lalanne, October 2023 (20 minutes)
In this episode Ben Scher talks to Professor Laurence Lalanne about drug consumption rooms and the recent publication based on the COSINUS cohort study. They cover the range of interventions available in drug consumption rooms and how they can increase people's access to psychiatric support alongside barriers to accessing drug consumption rooms. Laurence talks about the epidemiological point of view in relation to the more biomedical aspects of drug consumption rooms, their objectives in reducing overdose and their impact on hospitals and the wider health-care system.

19. Drug consumption rooms with Marie Jauffret-Roustide, October 2023 (37 minutes)
In this episode Ben Scher talks to Dr Marie Jauffret-Roustide about drug consumption rooms and the recent publication based on the COSINUS cohort study. They cover a range of issues including the history of drug consumption rooms, the evidence on effectiveness and the challenges of studying this particular intervention.They also reflect on the social determinants of health and how drug consumption rooms can have a positive impact

18. Drones delivering Naloxone with Caroline Copeland, Patrick Courtney and Paul Royall, October 2023 (28 minutes)
In this episode, Rob Calder talks to Drs Caroline Copeland, Patrick Courtney and Paul Royall about their recent article assessing the time it would take for drones to deliver naloxone to people who are overdosing on opioids. The study team used NPSAD (National Programme on Substance Abuse Deaths) data to map out overdoses in Teeside over recent years and then to predict how long it would have taken a drone to make the journey and deliver naloxone to a bystander who would then be able to administer it. They then compared this time with the time it takes ambulances to attend the scene. Along the way they discuss take off stations, weather, traffic congestion, no-fly zones and the importance of considering whether a drone will be destroyed along the way.

17. Canadian low-risk drinking guidelines with Dr Catherine Paradis, October 2023 (40 minutes)
In this episode Dr Merve Mollaametoglu talks to Dr Catherine Paradis director of health promotion and scientific alcohol lead at the Canadian Centre of Substance Use and Addiction, Dr Kevin Shield from the Centre for Addiction and Mental Health in Toronto and Dr Peter Butt clinical associate professor Department of Family Medicine at the University of Saskatchewan. They discuss their recent article looking at ways of making of low-risk alcohol drinking guidelines. They talk about how difficult it is to reach consensus on low-risk alcohol thresholds and how scientific evidence and public opinion meet. And the development of their ‘risk-zone’ approach. And how this can be interpreted by people who had differing perceptions of risk.

16 Social media and alcohol with Brandon Cheng, September 2023 (17 mins) 
Dr Elle Wadsworth talks here to Brandon Cheng about his research on social media posting and drinking behaviour. Brandon talks about the influence that media and social media have on young people and how they can influence their drinking behaviour. “A young person watching a short video of people enjoying drinks [is] likely to develop a much more vivid imagery of what drinking can be like … compared to a viewer just to see an image or text relating to someone having a good time drinking.” Original article: A systematic review and meta-analysis of the relationship between youth drinking, self-posting of alcohol use and other social media engagement (2012 – 2021) by Brandon Cheng and colleagues. Published in Addiction (2023). 

15. Cannabis, sport and anti-doping regulations with Tom Hudzik, September 2023 (23 minutes)
In this episode Dr Rob Calder talks to Dr Thomas Hudzik about his work with the World Anti Doping Agency (WADA). Tom talks about the three principles by which a substance is assessed and how they use the latest research and policy changes to make decisions about whether a substance is banned and how it is detected. They specifically cover the decision to implement and in-competition ban cannabis and the basis on which that decision was made. "The substance use can represent a risk to the athlete's health them-self or the health of those around them.... somebody who is allowed to perform in a group type of situation, their judgement will be impaired most likely. And that may affect the score that you have, but it could also mean that you do something silly physically that you might not have done otherwise because your reaction time is slow, your temporal estimation capabilities are slow." Original article: Cannabis and sport: A World Anti-Doping perspective by Thomas Hudzik and colleagues. Published in Addiction (2023)

14. Fentanyl, poly-substance use and the US opioid epidemic with Joseph Friedman September 2023 (15 mins)
Ben Scher talks to Dr Joseph Friedman about his research on fentanyl overdoses. Joseph explains the four waves of opioid overdoses in the US and how opiate and opioid overdoses have changed. They discuss how patterns of poly-substance use are different across the US and how the combination of fentanyl and methamphetamines is become more prevalent across states. Along with the challenges of standardising results when coroners’ reports vary across the US. One of the main takeaways here is just understanding that poly-substance drug overdose is really becoming the norm….The percent of US overdose deaths involving both fentanyl and stimulants in 2010 was 0.6% so one in every 200 overdose deaths and by 2021 it rose to one-third of all [overdose] deaths. Original article: Charting the Fourth Wave: Geographic, Temporal, Race/Ethnicity, and Demographic Trends in Polysubstance Fentanyl Overdose Deaths in the United States, 2010-2021 by Joseph Friedman and colleagues.  

13. Vaping and smoking cessation with Vassilis Sideropoulos (24.04) August 2023
Rob Calder talks to Vassilis Sideropoulos about a recent paper on the role of vaping products in smoking cessation. The first author for this paper was Dr Catherine Kimber. Vassilis talks about the array of components that can contribute to quitting smoking when using vaping products. He summarises the research team’s work on identifying which combinations of support types are most effective. He talks about their research into advice on vaping products, nicotine strength and e-liquid flavours, as well as providing information on the relative harms of vaping and smoking and text message support. There's so many different flavours right now you can pick up almost anything now..... it's a massive raise and I think that's why flavour is a component that we need to understand better. Vassilis also talks about the challenges of recruiting participants from social media and how to exclude bots from your research participant group. Original article: E-cigarette support for smoking cessation: Identifying the effectiveness of intervention components in an on-line randomized optimization experiment by Catherine Kimber and colleagues. Published in Addiction (2023)

12. Overdose risk, opioid agonists and other medications with Eleni Domzaridou (18:21) August 2023
Rob Calder talks to Dr Eleni Domzaridou about her recent article on the risk of overdose among people prescribe medication for opioid use at the same time as being prescribed other medication - such as for mental health disorders. People who use opioid drugs are often prescribed drugs for physical or mental health problems or for pain management. Eleni and the research team studied non-fatal overdoses among this group of people. In this podcast, Eleni outlines why the marker of non-fatal overdose is important when seeking to prevent fatal overdoses. Eleni also talks about the challenges and practicalities of using a large data-set with data from GP surgeries to draw conclusions about associations between prescribed drug use and overdoses. There is an elevated non-fatal overdose risk for patients prescribed opioid agonists concurrently with benzodiazepines, gabapentinoids, z-drugs or antipsychotics. 

11. Methamphetamine, psychosis and family history with Rebecca McKetin (18:26) August 2023
In this episode Ben Scher talks to Dr Rebecca McKetin about her recent article looking the relationship between psychosis, psychotic symptoms and methamphetamine use. They discuss the implications and talk about who exactly is at risk of methamphetamine-related psychosis. Along the way, they cover the background of methamphetamine use in Australia and how this varies from country to country.They then discuss the relative risk for psychotic symptoms among people with and without a family history of psychosis. The risk also changes when people are (or are not) actively using methamphetamine. Rebecca also talks about the potential for people to progress to schizophrenia and how treatment services should respond. Rebecca talks about the range of interventions that could be used to address methamphetamine related risks use and drug-related mental health problems.We need to target methamphetamine use as a risk factor for psychosis, regardless of whether people have a history of psychosis on their family.... the other one is that we need to be looking at people who do have a family history of psychosis at being at very high risk of having psychotic symptoms.Original article: How does a family history of psychosis influence the risk of methamphetamine-related psychotic symptoms: Evidence from longitudinal panel data by Rebecca McKetin and colleagues. Published in Addiction (2023)

10. Perspectives on gambling from 1561 with Louise Nadeau (23:09) July 2023
In this episode Ben Scher talks to Professor Louise Nadeau about her recent article anaysing the content of a Latin-language treatise on gambling addiction written nearly 500 years ago. Ben and Louise discuss the medical model of gambling and issues of historic identification. They unpick how the original authors wrote about the medical model of addiction long before it was called that. Parts of the treatise refer to non-problematic gambling - noting that there was a small population who had problems. There are also references to gambling harms and models of treatment that go back to the 6th century AD. This podcast offers a fascinating historical insight in a way that illuminates our current understanding of addiction and co-occurring disorders."So here was this person in 1561 who was thinking of erroneous cognitions who thought of genetic vulnerability - all that at the end of the Renaissance."Original article: A re-discovered treatise from 1561 by Louise Nadeau and Marc Valleur. Published in Addiction (2023)

9. Hallucinogen use, young adults and monitoring the future with Katherine Keyes (23:06) August 2023
In this episode, Dr Elle Wadsworth talks to Dr Katherine Keyes about her study examining changes to hallucinogen use among young adults in the US. Katherine also talks about using the Monitoring The Future survey to identify patterns of substance use among young adults."...going from 2020 to 2021 we really saw substantial increases in the prevalence of young adults who are reporting that they use hallucinogens other than LSD. And we didn't see the same trend of use of LSD."Original article: Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021 by Katherine M. Keyes and colleagues. Published in Addiction (2023)

8. Risk of bias in tobacco cessation trials with Jamie Hartmann-Boyce (20:12) July 2023
In this episode, Chloe Burke talks to Dr Jamie Hartmann-Boyce about new guidance from the Cochrane Tobacco Addiction Group (TAG) on assessing and minimising risk of bias in tobacco cessation trials. Jamie explains some of the key challenges in this area and explains some of the primary sources of bias that authors need to be aware of when analysing tobacco cessation trials. This article was published as part of Addiction's Methods and Techniques series."We wanted to do this to make sure people were assessing it [risk of bias] well, but also to put in some sort of consistency across our reviews so that the different author teams working on them were broadly using the same criteria"Original article: Assessing and minimizing risk of bias in randomized controlled trials of tobacco cessation interventions: Guidance from the Cochrane Tobacco Addiction Group by Jamie Hartmann-Boyce and Nicola Lindson. Published in Addiction (2023)

7. Cannabis legalisation in Canada with Janni Leung (25:55) July 2023
In this episode, Dr Elle Wadsworth talks to Dr Janni Leung about her work on a systematic review of the evidence on cannabis arrests, cannabis products and prices since Canada legalised cannabis. Janni talks discusses how arrest figures have changed, along with trends in legal and illicit purchase of cannabis. She covers issues relating to cannabis packaging and the potential for this to have a In this episode, Dr Elle Wadsworth talks to Dr Janni Leung about her work on a systematic review of the evidence on cannabis arrests, cannabis products and prices since Canada legalised cannabis. Janni talks discusses how arrest figures have changed, along with trends in legal and illicit purchase of cannabis. She covers issues relating to cannabis packaging and the potential for this to have an impact on people who do not purchase cannabis. They also discuss cannabis legalisation in the context of driving and traffic-related injuries. "We found that after cannabis legalisation there have been significant reductions in cannabis arrests. This means that less police time and efforts have been spent arresting people for cannabis use" Original article: The implementation and public health impacts of cannabis legalization in Canada: a systematic review by Wayne Hall and colleagues. Published in Addiction (2023)

6. Bacterial infections and social determinants of health with Thomas Brothers (21:17) July 2023
In this episode Ben Scher talks to Dr Thomas Brothers about his qualitative systematic review looking at infections from injecting drug use. Tommy and Ben talk about bacterial and fungal infections and how social and structural factors can have a detrimental impact on access to treatment and health outcomes for people who use drugs. Tommy discusses the differences between countries, highlighting that the prevalence of injecting drug use is not always matched by increases in infections from injecting drug use. They talk about the influence of fentanyl, changes in drug use, drug supply and drug policy, whilst noting that the study found increases in bacterial infections that could not always be explained by these factors.In many of these countries there's been worsening economic and equality, worsening homelessness and our findings suggest that those sorts of economic policy factors are playing a big role in making people vulnerable to infections.Tommy also talks to Ben about conducting a qualitative systematic review, discussing the three steps of using thematic synthesis methods.Original article: Social and structural determinants of injection drug use-associated bacterial and fungal infections: A qualitative systematic review and thematic synthesis by Thomas D. Brothers and colleagues. Published in Addiction (2023)

5. Cannabis and apps with Marleen Olthof and Matthijs Blankers (30:22) June 2023
In this episode, Rob Calder talks to Marleen Olthof and Dr Matthijs Blankers about their research into ICan - a digital health app designed to reduce cannabis use. They initially talk about the potential of using apps to improve health and support people who use drugs before also discussing how apps can improve access to support. “It’s a much smaller step to sign up for a digital intervention than to enter treatment”- Marleen Olthof They discuss how complicated it can be to 'blind' people to a particular condition when researching digital apps and the techniques they used to run a single-blind randomised controlled trial. They then discuss the implications of their findings. Matthijs discusses pre-registration and how this helped the team to prepare; and, how open science principles benefit researchers throughout the research cycle.Original article: A guided digital intervention to reduce cannabis use: The ICan randomized controlled trial by Marleen Olthof and colleagues. Published in Addiction (2023)

4. Long-acting buprenorphine with Jo Neale (25:32) June 2023 
Professor Joanne Neale talks to Addiction Audio about her latest research into how people feel during the first 72 hours of having long-acting buprenorphine (Buvidal). Jo talks about the recent history of this medication and how it predated the COVID-19 pandemic and was then brought to attention because it meant that people did not have to attend a pharmacy on a daily basis. Jo also talks about how this can be positive for some people but isn't appropriate for everyone. Jo discusses the gap in the literature around how people respond to long-acting buprenorphine when it is first administered. Jo presents data from the first wave of a longitudinal study examining people's experiences throughout the medication. The findings from this first set of data will be used to help people prepare for the effects and to know what to expect. Jo discusses using an embodiment and embodied cognition approach when analysing the data. This was chosen because the researchers saw how the data quickly became complex.

3. Smoking and Ecological Momentary Assessment with Olga Perski (37:33) May 2023
Dr Perski explains the evolution of Ecological Momentry Assessment (EMA) studies and how they have been used to collect granular data relating to everyday experiences. Olga's latest review focuses on EMA studies and smoking, looking at lapse and relapse. She talks about how EMA can be used to test and develop models and theories of addiction in ways that cross-sectional studies cannot. She also covers how you can use EMA to capture fluctuating and dynamic changes among people who use drugs."If we go back to thinking about more traditional survey based studies which would measure these constructs weeks apart - knowing that lapses can happen very rapidly in response to very rapidly increased cravings or a cue in the environment. For example, in a bar or restaurant where someone would pick up a cigarette that can very rapidly lead to a lapse. I think that helps emphasis the point that Ecological Momentary Assessment and maybe also sensor data is required in order to pick up these very very rapid fluctuations."Olga then talks about developing an appraisal tool for assessing the quality of EMA studies, which involves looking at reporting guidelines. She then talks about how and why open science principles can be applied to EMA studies.Original article: Within-person associations between psychological and contextual factors and lapse incidence in smokers attempting to quit: A systematic review and meta-analysis of Ecological Momentary Assessment studies by Olga Perski and Colleagues. Published in Addiction (2023)

2. The acute effects of cannabis with Will Lawn (32:07) April 2023
Rob talks to Dr Will Lawn about his research into the acute effects of cannabis on young people and adults. Will talks about setting up a study looking at young people and adults’ experiences of using cannabis with different levels of cannabidiol. He talks about the challenges of blinding participants to different types of cannabis; about how to manage the placebo effect when participants can become quickly aware of whether they have or have not had cannabis and the challenges of running a trial involving a controlled drug.He discusses the study’s findings that suggest that teenagers respond similarly to adults in the acute stages of cannabis use and experience the same short-term harms as adults.He also talks about the importance of selecting the best episode of The Simpsons for an academic study.“In the last four to five years there’s been a swing towards thinking CBD doesn’t really moderate the impact of THC at these kind of 1 to 30mg dose levels”Dr Will Lawn is a Lecturer at King’s College London Psychology DepartmentOriginal article: ‘The acute effects of cannabis with and without cannabidiol in adults and adolescents: a randomised, double-blind, placebo-controlled, crossover experiment by Will Lawn and colleagues. Published in Addiction (2023)

1. Heated tobacco products and nomenclature with Katie East (15:23) January 2023
In this episode, Dr Katherine East talks about her recent article on heated tobacco product use. When conducting this research, Katie talked to former and current smokers who use IQOS to understand the words they use to describe themselves and what they do in relation to heated tobacco products. Katie and Rob then talk about how the language can reflect identity and how this can influence the risk of people relapsing to smoking or other forms of nicotine use. They discuss the importance of social norms and how language can play a substantial role in shaping those norms. Katie explains why some potential words that might have been used have since been discarded, including “heaters” and “IQOSers”. They also talk about different social circumstances and how heated tobacco use, vaping and smoking identities interact. Link to Katie’s previous podcast“Lots of people refer to it as smoking still…. It also means less having to explain what it is because very few people have heard of IQOS”“The way that people refer to things and they way they think about themselves as product users can influence their behaviour.”“Whilst people referred to IQOS use as smoking they were very resistant to being identified as a smoker”. Original article: ‘It's not what you'd term normal smoking’: a qualitative exploration of language used to describe heated tobacco product use and associated user identity by Katherine East and colleagues. Published in Addiction (2022).